Semaglutide: difference between revisions
Diff·revision 18 → 19·12:57, 14 Feb 2025
Difference between revision 18 and revision 19 of Semaglutide. 9 lines changed; the page grew by 981 bytes.
| Revision 18 — 15:25, 21 Jan 2025 ComparisonCato (talk) add the structural figure and caption it properly 7,098 bytes +365 | Revision 19 — 12:57, 14 Feb 2025 FreightFenna (talk) fix the anchor on an internal link 8,079 bytes +981 | ||
|---|---|---|---|
| 17 | | Albumin binding = >99% | 17 | | Albumin binding = >99% |
| 18 | | Time to steady state = 4–5 weeks | 18 | | Time to steady state = 4–5 weeks |
| + | 19 | <!-- Engineering --> | |
| + | 20 | | Position 8 = α-aminoisobutyric acid (DPP-4 resistance) | |
| + | 21 | | Position 26 = C-18 diacid via γ-Glu-2×OEG | |
| + | 22 | | Position 34 = Lys→Arg (single acylation site) | |
| 19 | }} | 23 | }} |
| 20 | {{hatnote|For the oral formulation and its absorption enhancer, see [[Oral semaglutide]]. For the drug class, see [[GLP-1 receptor agonist]].}} | 24 | {{hatnote|For the oral formulation and its absorption enhancer, see [[Oral semaglutide]]. For the drug class, see [[GLP-1 receptor agonist]].}} |
| ⋮ | ⋮ | ||
| 53 | 57 | ||
| 54 | Results are means from trials that included intensive behavioural support and a structured escalation schedule. Individual response is widely distributed: in STEP 1 roughly a third of participants on active treatment lost 20% or more of body weight, and roughly one in seven lost less than 5%. The determinants of that spread are not established.{{r|wilding2021}} | 58 | Results are means from trials that included intensive behavioural support and a structured escalation schedule. Individual response is widely distributed: in STEP 1 roughly a third of participants on active treatment lost 20% or more of body weight, and roughly one in seven lost less than 5%. The determinants of that spread are not established.{{r|wilding2021}} |
| + | 59 | ||
| + | 60 | == Adverse effects == | |
| + | 61 | Gastrointestinal events predominate — nausea in roughly 40% of participants at the 2.4 mg dose, vomiting in about 24%, diarrhoea in about 30% — concentrated during escalation and declining with time at a stable dose. They accounted for most of the 7% discontinuation rate in STEP 1.{{r|wilding2021}} | |
| + | 62 | ||
| + | 63 | Cholelithiasis and cholecystitis occur more often than on placebo, a finding consistent across rapid weight loss by other means and probably not specific to the drug. Acute pancreatitis is rare and its causal relationship remains debated. The label carries a contraindication in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, derived from rodent C-cell tumour findings whose human relevance is unestablished.{{r|lincoff2023}} | |
| 55 | 64 | ||
| 56 | == References == | 65 | == References == |